Ublituximab Recruiting Phase 2 Trials for Chronic Lymphocytic Leukemia / Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia (CLL or SLL) / CLL Progression Treatment

Indications	Status	Purpose	Phase
DBCOND0028332 (Chronic Lymphocytic Leukemia) DBCOND0058460 (Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia (CLL or SLL)) DBCOND0124029 (CLL Progression)	Recruiting	Treatment	2

clinicaltrials.gov Identifier	Title	Drugs
NCT04149821	Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy	Ublituximab (DB11850) Umbralisib (DB14989)